Grace Lu-Yao, PhD, MPH
Philadelphia, PA 19107
(215) 955-5391 fax
PhD, Yale University
MPH, Yale University
BS, State University of New York at Stony Brooke
Taipei Medical College
Research Professor, Jefferson College of Population Health
Professor, Sidney Kimmel Medical College
Vice Chair, Population Science, Medical Oncology, Thomas Jefferson University
Associate Director, Population Science, Sidney Kimmel Cancer Center
Research Director, Neu Center for Supportive Medicine and Cancer Survivorship, Sidney Kimmel Cancer Center
Research & Practice Interests
Cancer Surveillance, Screening, and Treatment for Prostate Cancer
Outcomes Research and Cancer Epidemiology
Host Factors and Immunotherapy Outcomes
Soon after graduating from Yale, Dr. Lu-Yao worked with the world-renowned outcome research pioneer, Dr. John E. Wennberg, at Dartmouth Medical School, where she learned how to use outcomes research to provide critical data for shared treatment decisions as well as to improve patient care while reducing health care costs. Many of her research findings on cancer surveillance, screening, and treatment for prostate cancer have provided benchmark references.
As an Associate Director of Population Science at SKCC, Dr. Lu-Yao oversees the Transdisciplinary Integration of Population Science (TIPS) mechanism and is charged with providing a platform for population science researchers integrated within each SKCC research Program to connect and cultivate new research directions.
Most Recent Peer-Reviewed Publications
- Mortality and Hospitalization Risk Following Oral Androgen Signaling Inhibitors Among Men with Advanced Prostate Cancer by Pre-existing Cardiovascular Comorbidities
- Relationship between polypharmacy and inpatient hospitalization among older adults with cancer treated with intravenous chemotherapy
- Individual and joint effects of metformin and statins on mortality among patients with high-risk prostate cancer
- Comparative effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer
- Role of genetic testing for inherited prostate cancer risk: Philadelphia prostate cancer consensus conference 2017
- Effect of metformin and statin use on survival in pancreatic cancer patients: A systematic literature review and meta-analysis
- Differential and Joint effects of metformin and statins on overall survival of elderly patients with pancreatic adenocarcinoma: A large population-based study
- Validation of a Contemporary Five-tiered Gleason Grade Grouping Using Population-based Data
- Does Certificate of Need Minimize Intensity Modulated Radiation Therapy Use in Patients with Low Risk Prostate Cancer?
- Reply to Michael Froehner, Rainer Koch, Manfred P. Wirth's Letter to the Editor re: Grace L. Lu-Yao, Peter C. Albertsen, Dirk F. Moore, Yong Lin, Robert S. DiPaola, Siu-Long Yao. Fifteen-year Outcomes Following Conservative Management among Men Aged 65 Years or Older with Localized Prostate Cancer. Eur Urol 2015;68:805-11
- Primary radiotherapy vs conservative management for localized prostate cancer - A population-based study
- Fifteen-year outcomes following conservative management among men aged 65 years or older with localized prostate cancer
- Cancer-specific survival after metastasis following primary radical prostatectomy compared with radiation therapy in prostate cancer patients: Results of a population-based, propensity score-matched analysis
- Fifteen-year survival outcomes following primary androgen-deprivation therapy for localized prostate cancer
- Metabolic dysregulation of the insulin-glucose axis and risk of obesity-related cancers in the Framingham heart study-offspring cohort (1971-2008)
- Fracture after androgen deprivation therapy among men with a high baseline risk of skeletal complications
- Re: Radical prostatectomy versus observation for localized prostate cancer
- In regard to Shen et al
- Severe genitourinary toxicity following radiation therapy for prostate cancer - How long does it last?
- Does primary androgen-deprivation therapy delay the receipt of secondary cancer therapy for localized prostate cancer?